plasminogen activator inhibitor 1

Summary

Summary: A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activators.

Top Publications

  1. pmc PAI-1 in tissue fibrosis
    Asish K Ghosh
    Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Cell Physiol 227:493-507. 2012
  2. pmc Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells
    Kristin G Nørsett
    Physiological Laboratory, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
    Am J Physiol Gastrointest Liver Physiol 301:G446-53. 2011
  3. ncbi uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view
    Bernd R Binder
    Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 97:336-42. 2007
  4. ncbi Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1
    Li Jun Ma
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Diabetes 53:336-46. 2004
  5. ncbi Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
    M S Pepper
    Department of Morphology, University Medical Center, Geneva, Switzerland
    Arterioscler Thromb Vasc Biol 21:1104-17. 2001
  6. pmc Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
    D T Eitzman
    Division of Cardiology, University of Michigan Medical Center, Ann Arbor 48109, USA
    J Clin Invest 97:232-7. 1996
  7. pmc Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
    P Eriksson
    King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
    Proc Natl Acad Sci U S A 92:1851-5. 1995
  8. ncbi The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
  9. ncbi The plasminogen activator system and cancer
    Brandon McMahon
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Pathophysiol Haemost Thromb 36:184-94. 2008
  10. pmc The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans
    Maithili Sashindranath
    Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
    Brain 135:3251-64. 2012

Detail Information

Publications385 found, 100 shown here

  1. pmc PAI-1 in tissue fibrosis
    Asish K Ghosh
    Feinberg Cardiovascular Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    J Cell Physiol 227:493-507. 2012
    ..Paradoxically, PAI-1 deficiency promotes spontaneous cardiac-selective fibrosis. In this review, we discuss the significance of PAI-1 in the pathogenesis of fibrosis in multiple organs...
  2. pmc Gastrin stimulates expression of plasminogen activator inhibitor-1 in gastric epithelial cells
    Kristin G Nørsett
    Physiological Laboratory, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
    Am J Physiol Gastrointest Liver Physiol 301:G446-53. 2011
    ..We conclude that elevated plasma gastrin concentrations are associated with increased expression of gastric PAI-1, which may act to restrain gastrin-stimulated cell migration and invasion...
  3. ncbi uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view
    Bernd R Binder
    Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University of Vienna, Vienna, Austria
    Thromb Haemost 97:336-42. 2007
    ..This review will focus on the general mechanism of uPAR/uPA/PAI-1 interactions and signaling and the possible relevance of this system in vascular biology...
  4. ncbi Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1
    Li Jun Ma
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Diabetes 53:336-46. 2004
    Increased plasminogen activator inhibitor 1 (PAI-1) has been linked to not only thrombosis and fibrosis but also to obesity and insulin resistance. Increased PAI-1 levels have been presumed to be consequent to obesity...
  5. ncbi Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis
    M S Pepper
    Department of Morphology, University Medical Center, Geneva, Switzerland
    Arterioscler Thromb Vasc Biol 21:1104-17. 2001
    ..Antiproteolysis, particularly in the context of angiogenesis, has become a key target in therapeutic strategies aimed at inhibiting tumor growth and other diseases associated with neovascularization...
  6. pmc Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
    D T Eitzman
    Division of Cardiology, University of Michigan Medical Center, Ann Arbor 48109, USA
    J Clin Invest 97:232-7. 1996
    ..These results strongly support the hypothesis that alterations in fibrinolytic activity influence the extent of pulmonary fibrosis that occurs after inflammatory injury...
  7. pmc Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
    P Eriksson
    King Gustaf V Research Institute, Department of Medicine, Karolinska Institute, Karolinska Hospital, Stockholm, Sweden
    Proc Natl Acad Sci U S A 92:1851-5. 1995
    ..63 vs. 0.53). Both alleles bind a transcriptional activator, whereas the 5G allele also binds a repressor protein to an overlapping binding site. In the absence of bound repressor, the basal level of PAI-1 transcription is increased...
  8. ncbi The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
    ..Finally, preclinical studies show that either inhibition of uPA catalytic activity or prevention of uPA binding to its receptor reduces tumor growth, angiogenesis and metastasis...
  9. ncbi The plasminogen activator system and cancer
    Brandon McMahon
    Division of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Pathophysiol Haemost Thromb 36:184-94. 2008
    ..Information provided in this brief review is aimed to promote greater interest in the role of the plasminogen activator system in cancer...
  10. pmc The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans
    Maithili Sashindranath
    Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia
    Brain 135:3251-64. 2012
    ....
  11. ncbi Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
    Claudia Dellas
    Department of Cellular Biology, Division of Vascular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Thromb Haemost 93:631-40. 2005
    Although plasminogen activator inhibitor 1 (PAI-1) is one of the primary regulators of the fibrinolytic system, it also has dramatic effects on cell adhesion, detachment and migration...
  12. pmc Increased expression of the urokinase plasminogen activator system by Helicobacter pylori in gastric epithelial cells
    Susan Kenny
    Physiological Laboratory, School of Biomedical Sciences, University of Liverpool, Crown St, Liverpool L69 3BX, UK
    Am J Physiol Gastrointest Liver Physiol 295:G431-41. 2008
    ....
  13. ncbi The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity
    J Hoffstedt
    Departments of Medicine and Surgery, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Diabetologia 45:584-7. 2002
    b>Plasminogen activator inhibitor 1 (PAI-1) increases in several insulin-resistant conditions such as obesity...
  14. pmc Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts
    Rui Ming Liu
    Department of Environmental Health Sciences, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Biol Chem 285:16239-47. 2010
    ..RNA enhances TGF-beta1-induced phosphorylation of JNK and p38 as well as the expression of plasminogen activator inhibitor 1 (PAI-1), a TGF-beta-responsive gene involved in the pathogenesis of many diseases...
  15. ncbi Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity
    M C Alessi
    Laboratoire d Hématologie Faculté de Médecine Timone, Centre Hospitalier Universitaire Timone, Marseille, France
    Diabetes 49:1374-80. 2000
    In adipose tissue from both obese mice and humans, plasminogen activator inhibitor 1 (PAI-1) expression has been reported to be upregulated to levels of increased plasma PAI-1...
  16. ncbi Pleiotropic functions of plasminogen activator inhibitor-1
    H R Lijnen
    Center for Molecular and Vascular Biology, KU, Leuven, Belgium
    J Thromb Haemost 3:35-45. 2005
    ..It is not always clear if these functions depend on the antiproteolytic activity of PAI-1, on its binding to vitronectin or on its intereference with cellular migration or matrix binding...
  17. ncbi Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake
    Sabine Thuy
    Department of Nutritional Medicine 180a, University of Hohenheim, 70599 Stuttgart, Germany
    J Nutr 138:1452-5. 2008
    ..01), and sucrose (Spearman r = 0.70; P < 0.01). In conclusion, our results suggest that dietary fructose intake, increased intestinal translocation of bacterial endotoxin, and PAI-1 may contribute to the development of NAFLD in humans...
  18. ncbi The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system
    Rudolf Fuchshofer
    Department of Anatomy II, Friedrich Alexander University, Erlangen 91054, Germany
    Exp Eye Res 77:757-65. 2003
    ..Inhibition of MMP activity through elevated levels of TGF-beta2 might contribute to the increase in ECM in the trabecular meshwork of glaucomatous eyes...
  19. pmc Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals
    Koji Yamamoto
    First Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai, Showa, Nagoya 466 8550, Japan
    Proc Natl Acad Sci U S A 99:890-5. 2002
    ..These results suggest that the large induction of PAI-1 by stress increases the risk for thrombosis in the older populations, and that the adipose tissue may be involved...
  20. pmc PAI-1-dependent endothelial cell death determines severity of radiation-induced intestinal injury
    Rym Abderrahmani
    Laboratory of Radiopathology and Experimental Therapeutics, Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses, France
    PLoS ONE 7:e35740. 2012
    ..This study demonstrates that PAI-1 plays a key role in radiation-induced EC death in the intestine and suggests that this contributes strongly to the progression of radiation-induced intestinal injury...
  21. pmc TGF-β1 → SMAD/p53/USF2 → PAI-1 transcriptional axis in ureteral obstruction-induced renal fibrosis
    Rohan Samarakoon
    Center for Cell Biology and Cancer Research MC 165, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
    Cell Tissue Res 347:117-28. 2012
    ..Mechanisms discussed here appear to be operative in other renal fibrotic disorders and are relevant to the global issue of tissue fibrosis, regardless of organ site...
  22. pmc Coagulation markers in healthy human subjects exposed to diesel exhaust
    Chris Carlsten
    Department of Medicine, University of Washington, 4225 Roosevelt Ave NE, University of Washington, Campus Box 354695, Seattle, WA 98195, United States
    Thromb Res 120:849-55. 2007
    ..Diesel exhaust is a major contributor to urban PM, and we conducted a controlled human exposure of diesel exhaust in healthy subjects...
  23. ncbi TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells
    Begona Munoz-Garcia
    Renal and Vascular Research Laboratory, Instituto de Investigacion Sanitaria, Fundacion Jimenez Diaz, Autonoma University, Avd Reyes Católicos 2, 28040 Madrid, Spain
    Cardiovasc Res 89:225-33. 2011
    ..However, the role of the TWEAK-Fn14 axis in thrombosis has not been previously investigated...
  24. ncbi Multiple biomarkers for the prediction of first major cardiovascular events and death
    Thomas J Wang
    Framingham Heart Study, Framingham, MA, USA
    N Engl J Med 355:2631-9. 2006
    ..Few investigations have evaluated the incremental usefulness of multiple biomarkers from distinct biologic pathways for predicting the risk of cardiovascular events...
  25. ncbi Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment
    Ralf Peter Czekay
    Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Exp Biol Med (Maywood) 229:1090-6. 2004
    b>Plasminogen activator inhibitor 1 (PAI-1) is the primary physiological inhibitor of plasminogen activation in vivo, and thus it is one of the main regulators of the fibrinolytic system...
  26. ncbi Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans
    John N Fain
    Department of Molecular Sciences, College of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    Endocrinology 145:2273-82. 2004
    ..for 48 h released more prostaglandin E(2), IL-8, and IL-6 than adiponectin, whereas the release of plasminogen activator inhibitor 1 and hepatocyte growth factor was less than that of adiponectin but greater than that of leptin...
  27. ncbi Plasminogen activator inhibitor type 1 (PAI1) and platelet glycoprotein IIIa (PGIIIa) polymorphisms in Black South Africans with pre-eclampsia
    Rosemary J Pegoraro
    Department of Chemical Pathology, Nelson R Mandela School of Medicine, University of Natal, Durban, South Africa
    Acta Obstet Gynecol Scand 82:313-7. 2003
    ..Association of fibrin abnormalities with pre-eclampsia prompted this study to examine whether polymorphisms in the plasminogen activator inhibitor Type 1 and platelet glycoprotein IIIa genes constitute risk factors for this condition...
  28. pmc HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate
    Mi Hye Lee
    Division of Endocrinology, Metabolism, and Medical Genetics, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA
    J Lipid Res 51:2619-28. 2010
    ....
  29. ncbi Parametrial adipose tissue and metabolic dysfunctions induced by fructose-rich diet in normal and neonatal-androgenized adult female rats
    Ana Alzamendi
    Neuroendocrine Unit, IMBICE CONICET CICPBA, La Plata, Argentina
    Obesity (Silver Spring) 18:441-8. 2010
    ..In turn, these abnormalities enhance the risk of metabolic syndrome, obesity, type 2 diabetes, and cardiovascular disease...
  30. pmc Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction
    Kyosuke Takeshita
    Department of Cardiology, Nagoya University Graduate School of Medicine, Showa, Japan
    Am J Pathol 164:449-56. 2004
    ....
  31. pmc Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
    Zaid Al-Hamodi
    Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia
    Cardiovasc Diabetol 10:23. 2011
    ..The aim of this study was to investigate the association of tPA and its inhibitor PAI-1 with type 2 diabetes (T2D) and MetS and interrelationship between PAI-1 and tPA activities and antigens in Malaysian T2D and normal subjects...
  32. ncbi Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?
    M Cigolini
    Institutes of Clinical Medicine, University of Verona, Italy
    Atherosclerosis 143:81-90. 1999
    ..This cytokine, produced by human adipose tissue and causing insulin resistance, may be a link in the clinical relationship between insulin-resistance syndrome and increased PAI-1 plasma levels...
  33. pmc A PAI-1 mutant, PAI-1R, slows progression of diabetic nephropathy
    Yufeng Huang
    Fibrosis Research Laboratory, Division of Nephrology, University of Utah School of Medicine, Salt Lake City, Utah 84108, USA
    J Am Soc Nephrol 19:329-38. 2008
    ..Treatment with PAI-1R prevented these changes without affecting body weight, blood glucose, glycosylated hemoglobin, creatinine, or creatinine clearance; therefore, PAI-1R may prevent progression of glomerulosclerosis in type 2 diabetes...
  34. ncbi Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients
    I Ezzidi
    Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia
    Diabetes Metab 35:214-9. 2009
    ....
  35. ncbi Smad3-dependent induction of plasminogen activator inhibitor-1 in astrocytes mediates neuroprotective activity of transforming growth factor-beta 1 against NMDA-induced necrosis
    Fabian Docagne
    Universite de Caen, CNRS UMR 6551, Bd H Becquerel, B P 5229, 14074 Caen Cedex, France
    Mol Cell Neurosci 21:634-44. 2002
    ..Overall, this study underlines the critical role of the t-PA/PAI-1 axis in the regulation of glutamatergic neurotransmission...
  36. ncbi Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma
    Chia Jui Weng
    Graduate Institute of Applied Science of Living, Tainan University of Technology, Tainan, Taiwan
    Ann Surg Oncol 17:3394-401. 2010
    ....
  37. ncbi Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice
    N Nagai
    Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium
    J Thromb Haemost 3:1379-84. 2005
    ..Here, the effect of plasminogen activator inhibitor-1 (PAI-1), an endogenous inhibitor of t-PA, on ischemic infarct volume was studied...
  38. pmc New role of plasminogen activator inhibitor-1 in alcohol-induced liver injury
    Gavin E Arteel
    Department of Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville Health Sciences Center, Louisville, Kentucky 40292, USA
    J Gastroenterol Hepatol 23:S54-9. 2008
    ..These data support a role of PAI-1 in the initiation and progression of ALD, and suggest that PAI-1 may be a useful target for clinical therapy to halt or blunt disease progression...
  39. ncbi Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation
    Z Ma
    Department of Pediatrics, Harbor UCLA Medical Center, Division of Allergy and Immunology, Torrance, CA, USA
    Clin Exp Allergy 39:1136-44. 2009
    ..Further studies evaluating the mechanisms of PAI-1 action and regulation may lead to the development of a novel prognostic factor and therapeutic target for the treatment and prevention of asthma and other PAI-1-associated diseases...
  40. pmc Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy
    Fabien Milliat
    Laboratory of Radiopathology, Institute for Radiological Protection and Nuclear Safety, Fontenay aux Roses Unité Propre de Recherche et de l Enseignement Supérieur, Equipe d Accueil 2710, France
    Am J Pathol 172:691-701. 2008
    ..Together, these data demonstrate that PAI-1 plays a critical role in radiation-induced intestinal damage, suggesting that PAI-1 is an attractive target for preventing or reducing the side effects of radiation therapy...
  41. ncbi Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene
    Jurre Hageman
    Department of Radiation and Stress Cell Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
    Clin Cancer Res 11:5956-64. 2005
    ..This may play a role in patient-to-patient variations in susceptibility toward fibrosis after radiotherapy...
  42. ncbi Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study
    James B Meigs
    General Medicine Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, 02114, USA
    Diabetes 55:530-7. 2006
    ..09-1.77). We conclude that in this community-based sample, plasma markers of endothelial dysfunction increased risk of incident diabetes independent of other diabetes risk factors including obesity, insulin resistance, and inflammation...
  43. pmc Genetics and genomics in pediatric septic shock
    Hector R Wong
    Division of Critical Care Medicine, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Crit Care Med 40:1618-26. 2012
    ..This review will highlight studies in pediatric sepsis with a focus on gene association studies and genome-wide expression profiling...
  44. ncbi Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins
    Egbert K O Kruithof
    Division of Angiology and Hemostasis, University Hospital of Geneva, 24, Rue Micheli du Crest, 1211 Geneva, Switzerland
    Thromb Haemost 100:969-75. 2008
    ..In this review we summarize the findings on the effect of inflammation and statins on PAI-1 expression...
  45. ncbi Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
    Manfred Schmitt
    Frauenklinik der Technischen Universitaet Muenchen, Germany
    Expert Rev Mol Diagn 10:1051-67. 2010
    ..Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas...
  46. ncbi Antimetastatic potentials of flavones on oral cancer cell via an inhibition of matrix-degrading proteases
    Shun Fa Yang
    Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
    Arch Oral Biol 53:287-94. 2008
    ..However, the antimetastatic activities of flavones, one subclass of flavonoids, in human oral squamous carcinoma SCC-4 cells have not been understood clearly...
  47. ncbi Peritoneal response to pneumoperitoneum and laparoscopic surgery
    M Bergstrom
    Department of Surgery, Sahlgrenska University Hospital Ostra, Goteborg University, S 41685 Göteborg, Sweden
    Br J Surg 89:1465-9. 2002
    ..Local peritoneal fibrinolysis is a critical factor in adhesion development. The objective was to investigate fibrinolytic changes in the peritoneum during laparoscopic and open surgery...
  48. pmc Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
    H Taubert
    Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle Wittenberg, Halle, Germany
    Br J Cancer 102:731-7. 2010
    ..However, effects of co-expression of members of the uPA system in soft-tissue sarcoma (STS) patients at the protein level in both tumour tissue and serum have not been investigated yet...
  49. pmc Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome
    Lorraine B Ware
    Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Crit Care Med 35:1821-8. 2007
    ..However, direct evidence for the contribution of abnormalities in coagulation and fibrinolysis proteins to outcomes in patients with acute lung injury/acute respiratory distress syndrome is lacking...
  50. pmc Involvement of miR-30c and miR-301a in immediate induction of plasminogen activator inhibitor-1 by placental growth factor in human pulmonary endothelial cells
    Nitin Patel
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Biochem J 434:473-82. 2011
    ..Finally, plasma levels of miR-30c and miR-301a were significantly down-regulated in patients with SCA compared with normal controls. These results provide a post-transcriptional regulatory mechanism of PlGF-induced PAI-1 elevation...
  51. ncbi Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer
    Mijung Woo
    Department of Biology, Graduate School SungShin Women s University, Seoul, Korea
    J Gastroenterol Hepatol 22:1064-70. 2007
    ..The promoter and exon polymorphisms of their genes, which are known to affect the transcription of these genes, were assessed to correlate with colorectal cancer susceptibility...
  52. ncbi The orphan nuclear receptor Rev-erb alpha regulates circadian expression of plasminogen activator inhibitor type 1
    Jing Wang
    Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    J Biol Chem 281:33842-8. 2006
    ..Thus, our results suggest that Rev-erb alpha is a major determinant of the circadian PAI-1 expression and a potential modulator of the morning susceptibility to myocardial infarction...
  53. pmc Transforming growth factor-beta-dependent and -independent pathways of induction of tubulointerstitial fibrosis in beta6(-/-) mice
    Li Jun Ma
    Department of Pathology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Am J Pathol 163:1261-73. 2003
    ....
  54. ncbi Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition
    Ian B Copland
    Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Stem Cells 27:467-77. 2009
    ..Combining microarray and proteomic screens we identified plasminogen activator inhibitor 1 (PAI-1) as one factor consistently upregulated in our in vitro ischemia-mimicking conditions...
  55. ncbi Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells
    Jens Gaedeke
    Fibrosis Research Laboratory, Division of Nephrology, University of Utah, Salt Lake City, Utah, USA
    Kidney Int 66:112-20. 2004
    ..Here, we investigate curcumin's ability to modulate TGF-beta's profibrotic actions in vitro...
  56. ncbi Plasminogen activator inhibitor 1: physiological and pathophysiological roles
    Bernd R Binder
    Department of Vascular Biology and Thrombosis Research, University of Vienna, A 1090 Vienna, Austria
    News Physiol Sci 17:56-61. 2002
    b>Plasminogen activator inhibitor 1 (PAI-1) inhibits plasminogen activators (u-PA and t-PA) by forming stable complexes endocytosed via a low-density lipoprotein receptor superfamily member-dependent mechanism...
  57. ncbi Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
    Yoshimasa Aso
    Department of Internal Medicine, Koshigaya Hospital, Dokkyo Medical University, Saitama, Japan
    Front Biosci 12:2957-66. 2007
    ..PAI-1, an acute phase protein, also could be involved in vascular inflammation. PAI-1 may be associated not only systemically but also locally with development of CVD...
  58. ncbi Ionizing radiation shifts the PAI-1/ID-1 balance and activates notch signaling in endothelial cells
    Marion Scharpfenecker
    Department of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Radiat Oncol Biol Phys 73:506-13. 2009
    ..To investigate the mechanism of such capillary damage, we studied the effect of TGF-beta and Notch signaling in microvascular endothelial cells...
  59. pmc Linking cell structure to gene regulation: signaling events and expression controls on the model genes PAI-1 and CTGF
    Rohan Samarakoon
    Center for Cell Biology and Cancer Research, Albany Medical College, Albany, NY 12208, United States
    Cell Signal 22:1413-9. 2010
    ..g., PAI-1, and CTGF), as a therapeutic option for the treatment of fibrotic diseases...
  60. pmc Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction
    Arman T Askari
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Exp Med 197:615-24. 2003
    ..The mechanism appears to be due to decreased oxidative inactivation of plasminogen activator inhibitor 1 (PAI-1) in the MPO(-/-), leading to decreased tissue plasmin activity...
  61. ncbi The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin
    S Stefansson
    Biochemistry Department, J H Holland Laboratory, American Red Cross, Rockville, Maryland 20855, USA
    Nature 383:441-3. 1996
    ....
  62. pmc TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1
    Cynthia E Wilkins-Port
    Center for Cell Biology and Cancer Research, Albany Medical College, Albany, New York 12208, USA
    Cancer Res 69:4081-91. 2009
    ....
  63. ncbi Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study
    Ann Smith
    Department of Epidemiology and Public Health, Queen s University, Belfast BT12 6BJ, UK
    Circulation 112:3080-7. 2005
    ..This study examines 11 hemostatic markers that reflect different aspects of the coagulation process to determine which have prognostic value after accounting for conventional risk factors...
  64. ncbi Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study
    Andreas Festa
    Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78228 3900, USA
    Circulation 107:2422-7. 2003
    ..The 4G/5G polymorphism of the plasminogen activator inhibitor-1 (PAI-1) gene has been related to cardiovascular disease...
  65. pmc Sphingosine-1-phosphate and interleukin-1 independently regulate plasminogen activator inhibitor-1 and urokinase-type plasminogen activator receptor expression in glioblastoma cells: implications for invasiveness
    Lauren Bryan
    Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA
    Mol Cancer Res 6:1469-77. 2008
    ..the plasminogen activator system proteins, including the urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor 1 (PAI-1), and a receptor for uPA (uPAR)...
  66. ncbi Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
    N J Brown
    Departments of Medicine and Pharmacology, Pathology, and Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA
    Kidney Int 58:1219-27. 2000
    ....
  67. ncbi Fibrinolysis and host response in bacterial infections
    Simone Bergmann
    Max von Pettenkofer Institute, Ludwig Maximilians University of Munich, Munich, Germany
    Thromb Haemost 98:512-20. 2007
    ..Moreover, the role of factors of the fibrinolytic cascade in inflammatory host response due to different bacterial infections will be presented...
  68. ncbi Increased mortality in septic shock with the 4G/4G genotype of plasminogen activator inhibitor 1 in patients of white descent
    Gloria Garcia-Segarra
    Medical Intensive Care Unit, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Intensive Care Med 33:1354-62. 2007
    ..To evaluate the effect of the 4G/5G PAI-1 gene polymorphism on the development of organ failure and outcome in critically ill patients with septic syndromes...
  69. ncbi Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
    F Janicke
    Universitäts Frauenklinik Eppendorf, Hamburg, Germany
    J Natl Cancer Inst 93:913-20. 2001
    ..After 4.5 years, we present results of the first interim analysis...
  70. pmc Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1
    Charmi Shah
    Torrey Pines Institute for Molecular Studies, San Diego, California 92121, USA
    J Biol Chem 283:13538-48. 2008
    ..This study has identified a novel link between sphingolipid metabolism and PAI-1 and also suggests that ceramide may be an intermediary molecule linking elevated PAI-1 to insulin resistance...
  71. ncbi Ischaemic stroke subtypes and their genetic basis: a comprehensive meta-analysis of small and large vessel stroke
    Rohit Rao
    Imperial College Cerebrovascular Research Unit, Department of Clinical Neuroscience, Imperial College London and Hammersmith Hospitals, London, UK
    Eur Neurol 61:76-86. 2009
    ..The extent to which genetic effects on the different subtypes of small (SVD) and large vessel disease (LVD) ischaemic stroke differ remains controversial...
  72. pmc Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins
    Ralf Peter Czekay
    The Scripps Research Institute, Dept of Cell Biology, Div of Vascular Biology, 10550 N Torrey Pines Rd, VB 3, La Jolla, CA 92037, USA
    J Cell Biol 160:781-91. 2003
    ..This novel "deadhesive" activity of PAI-1 toward a variety of cells growing on different extracellular matrices may begin to explain why high PAI-1 levels often are associated with a poor prognosis in human metastatic disease...
  73. pmc Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
    Orla Cunningham
    FIRC Institute of Molecular Oncology, 20139 Milan, Italy
    Glia 57:1802-14. 2009
    ..the murine CNS expression of uPAR and uPA as well as that of tissue plasminogen activator and plasminogen activator inhibitor 1 (PAI-1) during insults generating distinct and well-characterized inflammatory responses; acute ..
  74. ncbi The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Biochem 37:541-8. 2004
    ..The measurement of uPA components, especially in breast cancer, thus has the potential to help with individualised patient management...
  75. ncbi The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability
    Sreerama Shetty
    Lab C 6, Biomedical Research Bldg, The Univ of Texas Health Science Center at Tyler, 11937 U S Hwy 271, Tyler, TX 75708, USA
    Am J Physiol Lung Cell Mol Physiol 295:L967-75. 2008
    ....
  76. ncbi Adipokines: the missing link between insulin resistance and obesity
    B Antuna-Puente
    INSERM U680, Faculte de Medecine Saint Antoine, Universite Pierre et Marie Curie Paris 6, 75012 Paris, France
    Diabetes Metab 34:2-11. 2008
    ....
  77. pmc Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial)
    Robert D McBane
    Division of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Cardiol 105:17-24. 2010
    ..Targeting the factors that led to the downregulation of PAI-1 in older patients with type 2 DM might offer an attractive strategy for reducing cardiovascular risk...
  78. pmc Reduced cardiac expression of plasminogen activator inhibitor 1 and transforming growth factor beta1 in obese Zucker rats by perindopril
    J E Toblli
    Laboratory of Experimental Medicine, Hospital Aleman, CONICET, Av Pueyrredon 1640, Buenos Aires 1118, Argentina
    Heart 91:80-6. 2005
    ..enzyme inhibition by perindopril can reduce cardiac transforming growth factor beta1 (TGFbeta1) and plasminogen activator inhibitor 1 (PAI-1) and therefore control collagen accumulation in an animal model with the metabolic syndrome ..
  79. ncbi Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties
    A Ojima
    Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan
    Horm Metab Res 44:501-5. 2012
    ..Our present study suggests that GIP could block the signal pathways of AGEs in HUVECs by reducing ROS generation and subsequent RAGE expression probably via GIP receptor-cyclic AMP axis...
  80. pmc Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis
    Kristine Marie Jessen
    Clinical Research Unit, Hvidovre University Hospital, Copenhagen, Denmark
    BMC Infect Dis 7:108. 2007
    ..Only few studies have combined the analysis of multiple SNPs in the same population...
  81. pmc Platelets retain high levels of active plasminogen activator inhibitor 1
    Helen Brogren
    Wallenberg Laboratory for Cardiovascular Research, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 6:e26762. 2011
    The vascular fibrinolytic system is crucial for spontaneous lysis of blood clots. Plasminogen activator inhibitor 1 (PAI-1), the principal inhibitor of the key fibrinolytic enzyme tissue-type plasminogen activator (tPA), is present in ..
  82. ncbi The MAPK pathway and HIF-1 are involved in the induction of the human PAI-1 gene expression by insulin in the human hepatoma cell line HepG2
    Elitsa Y Dimova
    University of Kaiserslautern, Faculty of Chemistry, Department of Biochemistry, Erwin Schroedinger Strasse 54, 67663 Kaiserslautern, Germany
    Ann N Y Acad Sci 1090:355-67. 2006
    ..Thus, insulin-dependent PAI-1 gene expression might be regulated by the action of both HIF-1 and FoxO1 transcription factors...
  83. ncbi Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer
    Raffaele Palmirotta
    Department of Laboratory Medicine and Advanced Biotechnologies, IRCCS San Raffaele Pisana, via della Pisana 235, Rome, Italy
    Thromb Res 124:403-8. 2009
    ..PAI-1 4G/5G polymorphism may have significance for antigen expression. Thus, we analyzed the possible associations between PAI-1 4G/5G polymorphism, plasma PAI-1 levels, and clinicopathological features of breast cancer (BC) patients...
  84. ncbi Increased vascular endothelial growth factor may account for elevated level of plasminogen activator inhibitor-1 via activating ERK1/2 in keloid fibroblasts
    Yidi Wu
    Department of Oral and Maxillofacial Surgery, Charles R Drew University of Medicine and Science, Los Angeles, CA 90059, USA
    Am J Physiol Cell Physiol 286:C905-12. 2004
    ..These findings suggest that VEGF may play an important role in keloid formation by altering ECM homeostasis toward a state of impaired degradation and excessive accumulation...
  85. ncbi Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome
    Stefano Palomba
    Department of Obstetrics and Gynecology, University Magna Graecia of Catanzaro, Catanzaro, Italy
    Fertil Steril 84:761-5. 2005
    ..with polycystic ovary syndrome, metformin administration, not laparoscopic ovarian drilling, reduces plasminogen activator inhibitor 1 (PAI-1) activity. The lack of a decrease in PAI-1 activity is related to a high risk for miscarriage.
  86. ncbi The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism
    M Stegnar
    University Medical Centre, Department of Angiology, Ljubljana, Slovenia
    Thromb Haemost 79:975-9. 1998
    ..Similar distribution of the 4G/5G genotypes in patients and healthy controls suggests that this genetic variation by itself is not a major risk factor for venous thromboembolism...
  87. pmc The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice
    Kristy A Bauman
    Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Clin Invest 120:1950-60. 2010
    ..These studies demonstrate crosstalk between plasminogen activation and PGE2 generation in the lung and provide a mechanism for the well-known antifibrotic actions of the fibrinolytic pathway...
  88. ncbi Metabolic, hormonal and environmental regulation of plasminogen activator inhibitor-1 (PAI-1) expression: lessons from the liver
    Elitsa Y Dimova
    Department Chemistry Biochemistry, University of Kaiserslautern, Kaiserslautern, Germany
    Thromb Haemost 100:992-1006. 2008
    ..This article will primarily focus on the regulation of PAI-1 expression in liver cells and discuss potential cross-talks between metabolic, hormonal and environmental signals...
  89. ncbi Transcriptional regulation of plasminogen activator inhibitor-1 expression by insulin-like growth factor-1 via MAP kinases and hypoxia-inducible factor-1 in HepG2 cells
    Elitsa Y Dimova
    Department Chemistry Biochemistry, University of Kaiserslautern, Germany
    Thromb Haemost 93:1176-84. 2005
    ..Thus, IGF-1 activates human PAI-1 gene expression through activation of the PI3-kinase and ERK1/2 via HIF-1alpha...
  90. pmc 4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study
    Krisztina Madách
    Department of Anesthesiology and Intensive Therapy, Semmelweis University, Kutvolgyi ut 4, Budapest, Hungary
    Crit Care 14:R79. 2010
    ..Elevated levels of PAI-1 have been related to worse outcome in pneumonia. We aimed to evaluate the effect of functionally relevant 4G/5G polymorphism of PAI-1 gene in pneumonia induced sepsis...
  91. ncbi Differential regulation of PAI-1 gene expression in human fibroblasts predisposed to a fibrotic phenotype
    P J Higgins
    Department of Microbiology, Immunology and Molecular Genetics, Albany Medical College, Albany, New York, 12208, USA
    Exp Cell Res 248:634-42. 1999
    ....
  92. ncbi Reactive oxygen species and matrix remodeling in diabetic kidney
    Hunjoo Ha
    Hyonam Kidney Laboratory, Soon Chun Hyang University, Seoul, Korea
    J Am Soc Nephrol 14:S246-9. 2003
    ..Precise definition of ROS-activated signaling pathways leading to ECM remodeling in the kidney will provide new strategies to prevent or treat diabetic renal injury...
  93. ncbi Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury
    William P Fay
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Trends Cardiovasc Med 14:196-202. 2004
    ..This review examines recent studies addressing the vascular function of PAI-1, and those assessing the role of fibrin as a downstream mediator of PAI-1's effects...
  94. pmc PAI-1 inhibits neutrophil efferocytosis
    Young Jun Park
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Proc Natl Acad Sci U S A 105:11784-9. 2008
    ..Our data therefore indicate that PAI-1 serves as a novel "don't eat me" signal for viable and apoptotic neutrophils...
  95. pmc Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice
    Susan Kenny
    Departments of Cell and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, United Kingdom
    Endocrinology 154:718-26. 2013
    ..Thus, gastric expression of PAI-1 is associated with hyperphagia, moderate obesity, and resistance to the satiating effects of CCK indicating a new role in suppressing signals from the upper gut that inhibit food intake...
  96. ncbi Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer
    B Märkl
    Institute of Pathology, Klinikum Augsburg, Augsburg, Germany
    J Surg Oncol 102:235-41. 2010
    ..The proteases PAI-1 and uPA play a major role in extracellular matrix degradation, which facilitates tumour progression. Tumour budding is a histomorphological expression of enhanced tumour cell migration...
  97. ncbi UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers
    K Malinowsky
    Department of Pathology, Technische Universitat Munchen, Trogerstraße 18, D 81675 Munich, Germany
    Curr Med Chem 17:4370-7. 2010
    ....
  98. ncbi The genetics of venous thromboembolism. A meta-analysis involving approximately 120,000 cases and 180,000 controls
    Reya Gohil
    Imperial College Cerebrovascular Research Unit, Hammersmith Hospitals and Imperial College, London W6 8RF, UK
    Thromb Haemost 102:360-70. 2009
    ..80; 95% CI 0.68-0.94, p = 0.007) and beta-fibrinogen 455 G/A (OR 0.84; 95% CI 0.72-0.97, p = 0.02) both showed significantly protective effects. Our work supports a genetic aetiology to VTE disease and provides reliable risk estimates...
  99. pmc TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling
    Rohan Samarakoon
    Albany Medical College, Center for Cell Biology and Cancer Research, MC 165, 47 New Scotland Avenue, Albany, NY 12208, USA
    J Mol Cell Cardiol 44:527-38. 2008
    ....
  100. ncbi Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice
    M B Grant
    Department of Medicine, University of Florida, Gainesville 32610 0226, USA
    Invest Ophthalmol Vis Sci 41:2296-302. 2000
    ..To determine whether overexpression of PAI-1 in cells of retinal microvasculature would result in a disease similar to that observed in diabetes, ocular tissue from transgenic mice that overexpress human PAI-1 were examined...
  101. ncbi Plasminogen activator inhibitor type-1 gene 4G/5G polymorphism in Turkish adult patients with asthma
    Didem Cosan
    Department of Medical Biology, Medical Faculty, Eskisehir Osmangazi University, Eskisehir, Turkey
    Genet Test Mol Biomarkers 13:543-6. 2009
    ....

Research Grants65

  1. Autonomic, Endothelial, and Inflammatory Correlates of Sleep Duration
    MERCEDES RENEE CARNETHON; Fiscal Year: 2012
    ..Findings from this study will suggest mechanisms to explain the prior observed associations between sleep duration and CVD risk factors. ..
  2. Metabolic regulation of diabetic nephropathy
    Karen Block; Fiscal Year: 2013
    ..This work may have major therapeutic implications. ..
  3. PlGF-HIF1a-miRNA Axis in Sickle Pulmonary Hypertension
    Punam Malik; Fiscal Year: 2013
    ..These studies will likely provide new diagnostic bio-markers for assessment of PHT, and novel therapeutic targets for a disease that currently has few or no therapeutic options. ..
  4. Dichotomous Roles of Thrombin in Acetaminophen Hepatotoxicity
    ROBERT ANDREW ROTH; Fiscal Year: 2013
    ..Elucidating mechanisms by which APAP-induced liver injury progresses is essential for defining novel strategies to prevent liver failure in patients and for the general understanding of the pathogenesis of drug-induced liver injury. ..
  5. Inflammation and Injury in Obesity Hypertension in African American Adolescents
    Bonita Falkner; Fiscal Year: 2010
    ..abstract_text> ..
  6. Vitamin D deficiency and treatment in male veterans at risk for diabetes
    Elena Barengolts; Fiscal Year: 2013
    ....
  7. Plasminogen activator inhibitor-1 in tumor progression and metastasis
    Yves A DeClerck; Fiscal Year: 2013
    ....
  8. PAI-1 and Vitronectin in Failure of Coronary Revascularization
    William P Fay; Fiscal Year: 2013
    ..This application will study the roles of plasminogen activator inhibitor-1 and vitronectin in the failure of percutaneous coronary interventions. ..
  9. Role of Fibrinolytic System in Vein Graft Remodeling
    William P Fay; Fiscal Year: 2013
    ..We anticipate that the information gained from our experiments will lead to new strategies to treat and prevent vein graft disease. ..
  10. Regulation of Transcriptional Activity of Hypoxia Inducible Factor 2
    Cheng Jun Hu; Fiscal Year: 2012
    ..First, HIF2( and USF2 share a large number of common target genes. An example of such gene is the plasminogen activator inhibitor 1 (PAI1)...
  11. Ah Receptor Anatomy: Implications for Dioxin Toxicity
    CORNELIS JOHAN ELFERINK; Fiscal Year: 2011
    ..Parallels between humans and mice in the re- generative response, instills confidence that findings generated during these studies will be directly applicable to the human condition. ..
  12. Regulation of Pal-1 in Atherosclerosis and Thrombosis
    Yolanda M Fortenberry; Fiscal Year: 2013
    ..This is particularly important, since to date, there are no PAI-1 inhibitors available for clinical use (End of Abstract) ..
  13. KLF2 as a regulator of endothelial cell biology
    MUKESH KUMAR JAIN; Fiscal Year: 2012
    ..abstract_text> ..
  14. Countermeasures for chlorine-induced airway fibrosis
    Gary W Hoyle; Fiscal Year: 2013
    ..This type of research is important because of concerns that U.S. civilians could be adversely affected by the accidental or intentional release of highly toxic chemicals such as chlorine. ..
  15. Interactions of Lipoproteins and Cells in Diabetes Mellitus
    RICHARD LOUIS KLEIN; Fiscal Year: 2013
    ..Collectively, these studies will elucidate for the first time the patterns of S1P metabolism in lipoproteins and in diabetes, and define the cellular and plasma mechanisms which mediate this metabolism. ..
  16. Pathogenesis of Lymphangioleiomyomatosis
    Lucia Schuger; Fiscal Year: 2010
    ..We believe that the new knowledge obtained from these studies will help to better understand the pathogenesis of LAM and to devise novel therapeutic strategies to treat this disease. ..
  17. Treatment and Risk Factor Determinants of Cardiovascular Outcomes in BARI 2D
    Maria Mori Brooks; Fiscal Year: 2013
    ..Such results would have important clinical implications for the treatment of the large and growing population of patients with type 2 diabetes and stable ischemic heart disease. ..
  18. Deleted in liver cancer 1 (DLC1) in liver development and disease
    Yi Ping Shih; Fiscal Year: 2013
    ..I have also discovered that loss of DLC1 enhances angiogenesis by upregulating VEGF and plasminogen activator inhibitor 1 (PAI-1) expression...
  19. Ah receptor transcriptional regulation through a novel DNA binding site
    SHELLY RENEE WILSON; Fiscal Year: 2012
    ..abstract_text> ..
  20. BMP Regulation of TGF-b2 in the Trabecular Meshwork
    Robert J Wordinger; Fiscal Year: 2012
    ..This study is relevant because it will examine the role of local growth factors in the control of eye pressure and may lead to new treatments for glaucoma. ..
  21. Preclinical Development of a Novel Plaque-Regressing Therapy For Atherosclerosis
    Michael W Fanger; Fiscal Year: 2012
    ..Success would ultimately provide a profound medical advancement in treatment of atherosclerosis, a significant benefit to human health, and a dramatic reduction in the economic impact of the number one killer in America. ..
  22. Exercise Effects on Serum Biomarkers of Angiogenesis
    CATHERINE ROSE DUGGAN; Fiscal Year: 2012
    ..The proposed study represents a unique opportunity to expand knowledge about the effects of physical activity on angiogenesis-related biomarkers, in a cost-effective and comprehensive manner by using an existing resource. ..
  23. Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)
    ANGARA KONETI RAO; Fiscal Year: 2013
    ....
  24. Urokinase, Neutrophil Activation and Acute Lung Injury.
    Gang Liu; Fiscal Year: 2013
    ..pathways, associated with increases in circulating and pulmonary concentrations of urokinase (uPA), plasminogen activator inhibitor 1 (PAI-1), and vitronectin, are present in almost all patients with acute lung injury (ALI)...
  25. Role of plasminogen activator inhibitor-1 in mediating age-related fibrosis
    David Lu; Fiscal Year: 2013
    ..Together, these findings may identify a novel PAI-1 dependent mechanism in which aged hearts are more prone to both fibrosis and attenuated wound healing following ischemic damage. ..
  26. The Role of PAI-1 and Circadian Disruption in the Pathogenesis of NASH
    Anne S Henkel; Fiscal Year: 2013
    ..These studies represent the progression in my long- standing research on the molecular pathogenesis of steatohepatitis and provide the platform for my development as an independent physician-scientist. ..
  27. The role of Plasminogen activator Inhibitor-1 in Helicobacter pylori infection.
    Sarah E Keates; Fiscal Year: 2010
    ..Results from these studies may lead to a better understanding of H. pylori pathogenesis and also the involvement of PAI-1 in the development and progression of human gastric cancer. ..
  28. Regulation of Host Response in S. pneumoniae Infections
    Jian dong Li; Fiscal Year: 2010
    ..abstract_text> ..
  29. Novel Targets in Thrombosis and Atherosclerosis
    Daniel A Lawrence; Fiscal Year: 2012
    ..The successful implementation of these goals should lead to a better understanding of the etiology of vascular disease and ultimately to improved treatments of thrombosis and vascular disease. ..
  30. CONTROL OF DRUG AND ETHANOL METABOLISM
    Gavin E Arteel; Fiscal Year: 2010
    ..e., fibrosis and cirrhosis). We therefore expect that the results of this work will identify targeting PAI-1 as a new potential therapy for ALD. ..
  31. tPA, white matter and cell therapy for stroke
    Yi Li; Fiscal Year: 2013
    ..Elucidating these cellular and molecular mechanisms will lead to improved restorative treatments for stroke and other forms of neural injury. ..
  32. "Validation of Novel CKD Biomarkers in CRIC"
    Kathleen D Liu; Fiscal Year: 2013
    ....
  33. Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus
    Maria F Lopes-Virella; Fiscal Year: 2011
    ....
  34. RESOLUTION OF GLOMERULOSCLEROSIS
    Agnes B Fogo; Fiscal Year: 2013
    ....
  35. Mechanism of PAI-1 Polarization to Myoendothelial Junctions
    Brant E Isakson; Fiscal Year: 2013
    ..The aggregate of the experiments will provide for the first time a pathological mechanism for the effect of increased PAI-1 seen in metabolic syndrome. ..
  36. Workshop on the Molecular and Cellular Biology of Plasminogen Activation
    Victoria Ploplis; Fiscal Year: 2013
    ..Continuation of this workshop will help to assure the development of the next generation of scientists who will become the future of this field. ..
  37. Allografts and Gene Therapy in Flexor Tendon Tissue Engineering
    Hani A Awad; Fiscal Year: 2013
    ..An experienced multi-disciplinary team has been assembled to conduct these studies that will test an innovative mechanistically-driven paradigm in flexor tendon tissue engineering with significant clinical implications. ..
  38. PAI-1 Targeted Intrapleural Fibronolytic Therapy
    Andrey Komissarov; Fiscal Year: 2012
    ..Ultimately, new interventions identified in this project could improve outcomes for thousands of afflicted US patients annually. ..
  39. HEMOSTATIC EFFECTS OF FIBRINOLYTIC THERAPY
    BARBARA ALEVRIADOU; Fiscal Year: 2000
    ....
  40. Mechanisms of Hemostatic Protease Inhibition by Serpins
    Ingrid M Verhamme; Fiscal Year: 2010
    ..They may facilitate development of novel anticoagulants based on HCII and DS specifically targeted to arterial thrombosis. ..
  41. PRESERVATION AND CARDIAC TRANSPLANT VASCULOPATHY
    David Pinsky; Fiscal Year: 2003
    ..These experiments will provide new insights into mechanisms by which early ischemic injury leads to early graft failure and TCAD, and proffer new strategies for prevention. ..
  42. CELLULAR MECHANISMS FOR ANGIOTENSIN RESPONSES IN BRAIN
    ELISABETH TALLANT; Fiscal Year: 1999
    ..These studies will extend our understanding of the role of the central RAS in blood pressure regulation and provide insight into the pathology of forms of essential human hypertension where endogenous levels of Ang II are elevated. ..
  43. ACE Inhibition and Novel Cardiovascular Risk Factors
    Marco Pahor; Fiscal Year: 2004
    ..abstract_text> ..
  44. GENETICS OF THE METABOLIC SYNDROME IN JAPANESE AMERICANS
    Melissa Austin; Fiscal Year: 2002
    ....
  45. MECHANISMS UNDERLYING CARDIOVASCULAR RISKS IN DIABETES
    Gordon Williams; Fiscal Year: 2000
    ..With this information, specific preventive and therapeutic measures could then be tested as to their efficacy in retarding the development of these complications. ..
  46. REGULATION OF ANGIOGENESIS BY PAI1
    Daniel Lawrence; Fiscal Year: 2001
    ..Finally, the role of PAI-1 in tumor angiogenesis will also be analyzed in congenic and xenograft models. ..
  47. WOUND HEALING ANGIOGENESIS
    Frank Isik; Fiscal Year: 2002
    ..The investigator will use a wound healing model in gene-targeted mice deficient in vitronectin, uPA, tPA, or uPAR to define the individual functions for vitronectin and the PA system for neovascularization after tissue injury. ..
  48. COMMON VARIANTS IN CANDIDATE GENES AND PREMATURE MI RISK
    Stephen Schwartz; Fiscal Year: 2001
    ....
  49. Enhancement of Thrombolysis through Inhibition of PAI-1 and Antiplasmin
    CHARLENE BLAKE; Fiscal Year: 2007
    ..The creation of this drug-antidote pair has the potential to reduce the amount of death and disability that results from stroke. [unreadable] [unreadable] [unreadable]..
  50. THROMBOPROPHYLAXIS IN THE SURGICAL SETTING
    Vladimir Muzykantov; Fiscal Year: 2004
    ..The results of this study may provide new means to achieve thromboprophylaxis in surgical settings such as angioplasty and endarterectomy, as well as be a platform for the development of novel forms of antithrombotic therapy. ..
  51. GENETIC ARCHITECTURE OF PLASMA T-PA AND PAI-1
    Jason Moore; Fiscal Year: 2004
    ..This collaborative proposal provides a robust mechanism for highly focused translational research in the molecular genetics and biology of the role of the fibrinolytic system in arterial and cerebral thrombosis. ..
  52. GENETIC VARIANTS AND THROMBOSIS
    Patricia Hebert; Fiscal Year: 2004
    ..This collaborative proposal provides a robust mechanism for highly focused translational research in the molecular genetics and biology of the role of the fibrinolytic system in arterial and cerebral thrombosis. ..
  53. Endocardial dysfunction in humans with AF
    HUA LINDA CAI; Fiscal Year: 2006
    ..was reduced in the endocardium in a porcine model of AF, whereas the pro-thrombotic protein plasminogen activator inhibitor 1 was upregulated...
  54. REGULATION OF VASCULAR FIBRINOLYSIS
    David Loskutoff; Fiscal Year: 2003
    b>Plasminogen activator inhibitor 1 (PAI-1) is the primary inhibitor of plasminogen activation and vascular fibrinolysis in vivo, and elevations in PAI-1 appear to compromise normal fibrin clearance mechanisms and promote pathological ..
  55. PLASMINOGEN ACTIVATOR INHIBITOR-1 IN ATHEROSCLEROSIS
    DANIEL EITZMAN; Fiscal Year: 2001
    ..Members of the Divisions of Cardiology and Molecular Medicine and Genetics will provide technical and academic support for this proposal. (End of Abstract) ..
  56. MECHANISMS OF CARDIOVASCULAR DISEASE IN OBESITY
    David Loskutoff; Fiscal Year: 2002
    ..Although plasminogen activator inhibitor 1 (PAI-1) is consistently and significantly elevated in the plasma of obese humans and is a known risk ..
  57. VITRONECTIN AND VASCULAR COMPLICATIONS OF DIAB
    DAVID SANE; Fiscal Year: 1999
    ..We will directly test this hypothesis by creating a hyperglycemic state in VN null mice and in a control strain. These studies could elucidate novel strategies to prevent the vascular manifestation of diabetes. ..
  58. PATHOGENESIS OF RADIATION-INDUCED KIDNEY INJURY
    Michael Robbins; Fiscal Year: 2004
    ..These studies offer the promise of developing rational therapeutic strategies directed at reducing the severity of this dose-limiting morbidity in human beings. ..
  59. VASCULAR DISEASE IN HBP--ANGII, PAI1, INSULIN AND GENES
    Gordon Williams; Fiscal Year: 2001
    ..With this information, specific preventive and therapeutic measures to retard the development of these complications could be proposed and tested in a clinical trial's format. ..
  60. MOLECULAR INTERACTIONS OF FIBRINOLYSIS
    John Anagli; Fiscal Year: 2005
    ..This project can provide a foundation at the molecular level for rational development of therapeutic agents to modulate PAI-1 activity. ..
  61. Genetics of Early Onset-Stroke
    Steven Kittner; Fiscal Year: 2007
    ..The proposed study will complement other association studies of older stroke patients and will be a continuing resource for understanding the genetic basis of stroke risk. ..
  62. AGE RELATED CONFORMATIONAL MODIFICATIONS OF PROTEIN
    Ari Gafni; Fiscal Year: 2003
    ..This characterization will be achieved by X-ray crystallography, and by using room temperature phosphorescence to detect conformational changes in real time. ..
  63. Computer Directed Photodynamic Therapy of Prostate Ca
    Jerzy Jankun; Fiscal Year: 2005
    ....
  64. PEPTIDE ANTAGONISTS TO TGF-BETA AS ANTITHROMBOTIC AGENTS
    George Cianciolo; Fiscal Year: 1992
    ..It is claimed that specific, potent TGF-beta antagonists offer the potential for development of a new class of drugs which regulate fibrinolysis...
  65. Tyrosine Phosphatases and Endothelial Dysfunction
    Hua Tang; Fiscal Year: 2004
    ..abstract_text> ..